Dr. Sanacora is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
34 Park St
Cnru At Cmhc
New Haven, CT 06519Phone+1 203-974-7560
Summary
- Dr. Sanacora completed an NIH sponsored Medical Scientist Training Program at the State University New York at Stony Brook, earning his Ph.D. in Physiology and Biophysics in 1992 and his M.D. degree in 1994. He then moved to Yale University where he completed the Clinical Neuroscientist Training Program Residency in the Department of Psychiatry, and an NIH funded Neuroimaging Scientist Training Program Fellowship. He is currently a Professor of Psychiatry at Yale and the Director of the Yale Depression Research Program. Dr. Sanacora’s work is concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders. His basic science laboratory explores the effects of chronic stress on cellular biology and behavior, and examines the molecular, cellular and behavioral effects of newly developed treatment strategies. His clinical laboratory employs novel imaging methodologies and biomarker assays to investigate the pathophysiology of neuropsychiatric disorders. In addition, he has served as principle investigator on several early phase clinical trials designed to test the efficacy and mechanisms of action of newly developed therapeutic agents. Reflecting his contributions to the field, Dr. Sanacora was elected a Fellow of the American College of Neuropsychopharmacology in 2012. He has also received the Anna-Monkia Stiftung international award for the investigation of the biological substrate and functional disturbances of depression in 2009 and the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the American College of Neuropsychopharmacology in 2011.
Education & Training
- Yale-New Haven Medical CenterResidency, Psychiatry, 1994 - 1998
- Stony Brook University Health Sciences Center School of MedicineClass of 1994
Certifications & Licensure
- CT State Medical License 1996 - 2024
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Ketamine for the Treatment of Depression in Parkinson's Disease Start of enrollment: 2021 Nov 23
Roles: Contact
Publications & Presentations
PubMed
- Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.Craig Chepke, Richard Shelton, Gerard Sanacora, Teodora Doherty, Palina Tsytsik
The International Journal of Neuropsychopharmacology. 2024-12-01 - Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.Randall L Morrison, Jaskaran Singh, Ella Daly, Maggie Fedgchin, Rachel Ochs-Ross
The International Journal of Neuropsychopharmacology. 2024-11-01 - The genetics of severe depression.Clio E Franklin, Eric Achtyes, Murat Altinay, Kala Bailey, Mahendra T Bhati
Molecular Psychiatry. 2024-10-15
Press Mentions
- 7 Things Everyone Should Know About AntidepressantsDecember 6th, 2024
- Matthew Perry’s Death Shines a Harsh Light on Ketamine TreatmentAugust 19th, 2024
- DEA Shuts down Telehealth Ketamine PrescriberMay 11th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: